Health and Fitness Health and Fitness
Fri, February 10, 2012
Thu, February 9, 2012

Perception, Opportunity in Volatility - Research &;; Analysis on VIVUS, Inc. and Eli Lilly &;; Co.


Published on 2012-02-09 06:07:53 - Market Wire
  Print publication without navigation


February 09, 2012 09:00 ET

Perception, Opportunity in Volatility - Research & Analysis on VIVUS, Inc. and Eli Lilly & Co.

HONG KONG--(Marketwire - Feb 9, 2012) - This morning, [ www.MarketFoundations.com ] announced new reports highlighting VIVUS, Inc. (NASDAQ: [ VVUS ]) and Eli Lilly & Co. (NYSE: [ LLY ]). Free research downloads are available at [ www.MarketFoundations.com/index.php?coa=VVUS&cob=LLY ].

Economic fundamentals leading into 2012 have set a generally positive pace with GDP growth likely to pick up through the coming year. However, there are several important caveats to note as the world economy continues to face headwinds and risks weigh to the downside. Positive outlooks are conditional on fiscal policy in payroll taxes and unemployment insurance benefits and upon the easing of the European debt situation. A repeat of volatility experience in 2011 is likely in 2012, as perceptions about the strength of the U.S. economy and the euro zone will vary over time as events unfold.

Despite the current situation, our team continues to identify high momentum situations with growth potential -- there remains strong opportunity within careful discretion.

Market Foundations is releasing new coverage on VIVUS, Inc. for its current position within the healthcare industry. VIVUS, Inc. is a biopharmaceutical company. The Company is engaged in development and commercialization of therapeutic drugs for large underserved markets, including obesity and related morbidities, such as sleep apnea and diabetes and men's sexual health. The full research report on VIVUS, Inc. (NASDAQ: [ VVUS ]) is available here: [ www.MarketFoundations.com/index.php?coa=VVUS ].

Market Foundations has released research on Eli Lilly & Co. for its changing role within the healthcare industry. Eli Lilly and Company discovers, develops, manufactures and sells products in one business segment, pharmaceutical products. It also has an animal health business segment. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico, and 17 other countries. Its products are sold in approximately 125 countries. The full research report on Eli Lilly & Co. (NYSE: [ LLY ]) is available here: [ www.MarketFoundations.com/index.php?cob=LLY ].

About Market Foundations
By providing members with financial information services, we provide the foundation investors need to build investing intelligence. The difference between consistently making good investments or bad investments is nothing more than the right information at the right time.


Contributing Sources